

# BRINZOLAMIDA/BRIMONIDINA

## Bibliografía

1. Ficha técnica Simbrinza®. Disponible en: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/003698/WC500170361.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003698/WC500170361.pdf)
2. Ficha técnica Azopt®. Disponible en: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/000267/WC500030367.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000267/WC500030367.pdf)
3. Fichas técnicas Brimonidina tartrato. AEMPS. CIMA. Disponible en: <http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=buscar>
4. Ficha técnica Azarga®. Disponible en: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/000960/WC500029827.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000960/WC500029827.pdf)
5. Ficha técnica Combigan®. Disponible en: [http://www.aemps.gob.es/cima/pdfs/es/ft/67438/FT\\_67438.pdf](http://www.aemps.gob.es/cima/pdfs/es/ft/67438/FT_67438.pdf)
6. Brinzolamida/brimonidina: EPAR All Authorised presentations. Disponible en: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_All\\_Authorised\\_presentations/human/003698/WC500170363.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_All_Authorised_presentations/human/003698/WC500170363.pdf)
7. Aung T, Laganovska G, Hernandez TJ, et al. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. *Ophthalmology* 2014;121(12):2348-55.
8. Gandolfi SA, Lim J, Sanseau AC, et al. Randomized trial of brinzolamide/brimonidina versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. *Adv Ther* (2014) 31:1213-1227.
9. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014;121(11):2081-90.
10. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90:262-7.
11. Kingman S. Glaucoma is second leading cause of blindness globally. *Bull World Health Organ* 2004; 82:887
12. Jacobs DS. Uptodate. Open-angle glaucoma: Epidemiology, clinical presentation and diagnosis.
13. National Institute for Health and Clinical Excellence. Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. 2009. Disponible en: <https://www.nice.org.uk/guidance/cg85/resources/glaucoma-diagnosis-and-management-975690568645>
14. Van der Valk, Webers C, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. *Journal of Clinical Epidemiology* 2009; 62:1279e1283.
15. European Glaucoma Society: Terminology and Guidelines for Glaucoma. 4º ed. Disponible en: [www.eugs.org](http://www.eugs.org)
16. Primary Open-Angle Glaucoma. American Academy of Ophthalmology
17. Cheng JW, Cheng SW, Gao L. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. *Plos One* 2012; 7(9) | e45079